LuminX Biotech Co., Ltd.

LuminX was founded in 2020 with the hope of becoming the preclinical standard for all cellular products before they enter clinical trial, with the ultimate goal of being written into the guidelines.

LuminX Tracking Kit (LTK) is not only non-toxic, stable and long-lasting, but also can label 90% of the cells on the market (recently launched the third generation of reagents to label immune cells), which meets most of the needs in clinical trials.
Currently, the company has launched three platforms for three major markets (cancer, regenerative and immune therapy), hoping to attract a large number of users to use our product/services.

LuminX dedicates to accelerate the optimization of cell-therapy-products through specific understanding of therapeutic cells distribution in-vivo, long-term viability, as well as their biological fate.

With our patented LuminX Tracking Kit(LTK), out client can understand the systemic safety and biological fate of cells, estimate the outcome of cell therapy products, shorten the R&D process, and predict the clinical outcomes and improve the quality of patient’s life.

Our main business model objective is to seek commissioned cases and reagent sales with research, hospital-based and CRO companies. Move towards the simultaneous development, database increase and optimization of LuminX Tracking Kit. This process follows 3 key activities:【Cell localization, quantification and tracking】【Safety & efficacy data】【Meets FDA guidelines】

NBIC, iCANxIPAS, BE x TMU, Tacc+, NBRP, NHRI-TTIC